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Liposomes are self-assembling colloidal particles comprising a
lipid bilayer and an enclosed fraction of the surrounding aqueous
medium (Lasic and Papahadjopoulos, 1995). After their original
description more than 30 years ago (Bangham et al, 1965), it was
postulated that they would become an important vehicle for
targeted drug delivery in a range of clinical situations including
cancer therapy (Gregoriades et al, 1974). However, subsequent
studies highlighted the limitations of these conventional lipo-
somes, in particular their rapid clearance by the reticulo-endothe-
lial system (RES), unpredictable patterns of extravasation and lack
of long-term physicochemical stability (Gabizon 1994). As a
result, clinical applications of liposomes have been largely
restricted to situations in which targeting of the RES is desirable,
such as the treatment of systemic protozoal and fungal infections
(Russo et al, 1996; Ng and Denning, 1995).
However, in the last decade, the development of sterically
stabilized liposomes has renewed interest in the use of liposomes
to treat cancer. The lipid bilayer of sterically stabilized liposomes
is modified by the addition of glycolipids (Allen and Chonn,
1987), phosphatidylinositol (Gabizon and Papahadjopoulos, 1988)
or methoxypoly(ethylene glycol) (MPEG)-derivatized lipid
(Papahadjopoulos et al, 1991). The latter furnishes a steric barrier
against interactions with plasma proteins, such as opsonins and
lipoproteins, and cell-surface receptors. As a result, pegylated
liposomes are better able to evade the RES and remain in circula-
tion for prolonged periods, thereby conferring on entrapped
agents the pharmacokinetic profile of the lipid carrier, rather than
that of the free drug (Gabizon and Papahadjopoulos, 1988;
Paphadjopoulos et al, 1991; Gabizon et al, 1994). For this reason,
these liposomes have also been called ‘Stealth’ liposomes.
Pegylated liposome accumulation in tumours by means of extrava-
sation through leaky vasculature has been demonstrated by elec-
tron microscopic examination of C26 colon cancer xenografts and
Kaposi’s sarcoma-like lesions in mice (Huang et al 1992; 1993).
Preclinical studies have shown that cytotoxic drugs entrapped in
pegylated liposomes are active against a range of tumours
(Mayhew et al, 1992; Vaage et al 1992; 1993a, 1993b; 1994; 1995;
1999; Williams et al, 1993; Siegal et al, 1995, Newman et al,
1999). In clinical studies, pegylated liposomal doxorubicin has
been shown to have substantial activity against AIDS-related
Kaposi’s sarcoma, (Harrison et al, 1995; Goebel et al, 1996;
Northfelt et al, 1998; Stewart et al, 1998) and breast and ovarian
cancers (Muggia et al, 1997; Ranson et al, 1997).
In addition, liposomal formulation attenuates the familiar acute
(alopecia, nausea and vomiting and local vesicant activity) and
chronic (drug-induced cardiomyopathy) toxicities of unencapsu-
lated doxorubicin (Harrison et al, 1995; Madhavan and Northfelt,
1995; Berry et al, 1996). However, alteration of the pharmaco-
kinetics and biodistribution of agents by encapsulation within
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pegylated liposomes has been associated with novel toxic effects.
In particular, plantar-palmar erythrodysaesthesia (PPE) or
‘hand–foot’ syndrome is seen in patients treated with repeated
doses of pegylated liposome-encapsulated doxorubicin. This toxi-
city, which manifests as painful swelling and erythema of the
hands, feet, intertriginous areas and sites of trauma, is thought to
be the result of accumulation of liposomal doxorubicin in the skin
with the effect of delivering a prolonged drug exposure (Gordon
et al, 1995).
In view of the flexibility of pegylated liposomes as a delivery
system, it is likely that novel therapeutic strategies incorporating a
range of anti-cancer agents, including cytotoxic drugs, radiation
sensitizers and therapeutic beta-emitting radionuclides, will be
investigated. In this study we report in detail the biodistribution
and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes
and unencapsulated 111In-DTPA in nude mice bearing a human
head and neck squamous cell cancer xenograft. These data provide
important information on the tissues targeted by pegylated lipo-
somes and the extent and time-course of uptake. The potential
application of novel targeting approaches are discussed in light of
the findings of this study.
MATERIALS AND METHODS
Animals and tumour model
Female nude mice of mixed genetic background were used in
these experiments. The animals were bred under specific
pathogen-free conditions at the Imperial Cancer Research Fund
Animal Breeding Unit, South Mimms, Hertfordshire, UK.
Thereafter, the animals were housed in sterile filter-top cages on
sterile bedding, and maintained on an irradiated diet and auto-
claved, acidified water (pH 2.8).
The human tumour KB cell-line was derived from a male
patient with a poorly differentiated squamous cell cancer of the
floor of mouth and tongue and established in cell culture in 1954
(Eagle, 1955). KB tumour cells were grown to confluence in vitro
in RPMI-1640 medium containing 100 U ml–1 penicillin and
100 mg ml–1 streptomycin, supplemented with 10% foetal calf
serum (FCS) (Gibco, Paisley, UK) at 37°C in a humidified atmos-
phere of 5% CO2 in air. Tumour cells were harvested by brief
incubation with trypsin/versene and a single-cell suspension was
prepared. Tumour xenografts were established by injecting 5 ´ 106
tumour cells in 0.1 ml of culture medium subcutaneously into the
right flank of the mice. The animals were used for experiment
approximately 14 days after tumour inoculation.
Liposome labelling with 111In-oxine
Diethylenetriaminepentaacetic acid (DTPA, Janssen Chimica,
Geel, Belgium) was entrapped by SEQUUSTM Pharmaceuticals
Inc. in a proprietary pegylated liposome matrix with the following
lipid composition (values expressed in % molar ratio): hydro-
genated soybean phosphatidylcholine (HSPC) (56.2%), choles-
terol (38.3%), and N-(carbamoyl-methoxypolyethylene glycol
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium
salt (MPEG-DSPE) (5.3%). Liposomes were labelled by
incubating 2 ml of 111In-oxine (Amersham International plc,
Amersham, UK) with 20 ml of DTPA-containing pegylated lipo-
somes. Four milligrams of ethylenediaminetetraacetic acid
(EDTA) (BDH Ltd, Poole, UK) was added to chelate any residual
free 111In and promote its prompt excretion following intravenous
injection. Entrapment of 111In within the pegylated liposomes was
assayed by loading a 10 ml sample on to a 20 ml Sephadex G-50
column (Pharmacia, Uppsala, Sweden). Thirty consecutive 1 ml
fractions were eluted with phosphate buffered saline (PBS) and the
activity of each fraction was counted in a Canberra Packard
Minaxi 5550 gamma counter (Pangbourne, Berkshire, UK). The
entrapment was typically found to be greater than 90%.
Preparation of 111In-DTPA
40 ml of a solution of InCl3 in 0.04 M HCl containing 22.2 MBq
(600 mCi) of radioactivity was titrated to pH 6.0 by the addition of
60 ml of a 3.5% solution of sodium citrate. Thereafter, 10 ml of
DTPA, in 10-fold molar excess relative to the InCl3, and 100 ml of
a 100 mM solution of sodium acetate (pH 6.0) was added. The
final solution was diluted with PBS to a final activity of 10 mCi per
100 ml.
Determination of biodistribution and pharmacokinetics
of 111In-DTPA-labelled pegylated liposomes
KB tumour-bearing nude mice received 100 ml of 111In-DTPA-
labeled pegylated liposomes, containing 0.37–0.74 MBq (10–20
mCi) of radioactivity, as an intravenous bolus injection via a lateral
tail vein. The approximate phospholipid dose per mouse was 1.87
mg of HSPC and 0.64 mg of MPEG-DSPE per 100 ml injection.
Mice were killed by exsanguination at 1, 4, 24, 48, 72, 96, 144 and
240 h after the injection of pegylated liposomes. Tumour and
normal organs and tissues were dissected at each time-point and
their radioactivity was determined by counting pre-weighed tubes
in the gamma counter. Standards of the injected material were
made in triplicate and used to correct for decay of the 111In.
Determination of biodistribution and pharmacokinetics
of unencapsulated 111In-DTPA
KB tumour-bearing nude mice received 100 ml of 111In-DTPA
containing 0.37 MBq (10 mCi) of radioactivity as an intravenous
bolus injection via a lateral tail vein. Mice were killed by exsan-
guination at 5 min, 30 min, 1, 4, 24, 48 and 72 h after the injection
of  111In-DTPA. Tumour and normal organs and tissues were
dissected at each time-point and their radioactivity was determined
by counting pre-weighed tubes in the gamma counter. Standards of
the injected material were made in triplicate and used to correct for
decay of the 111In.
Incubation of 111InCl3, 111In-DTPA and in vitro stability of
111In-DTPA-labelled pegylated liposomes in human
serum
A solution of 111InCl3 containing 3.37 MBq (91.1 mCi) of activity
was added to 10 ml of human serum to achieve a final activity of
0.337 MBq ml–1 (9.1 mCi ml–1), in order to reproduce the maximal
initial concentration in mouse serum in the in vivo studies
(assuming mouse blood volume to be 1.8 ml and packed cell
volume to be 40%). Samples of 500 ml were taken at 5 min, 24 and
120 h, filtered through a 0.2 mm filter (Acrodisc, Gelman
Sciences, Ann Arbor, USA) and run on a Superose-6 FPLC
column. Eighty fractions of 0.5 mL were collected and counted in
the gamma counter.234 KJ Harrington et al
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Similarly,  111In-DPTA containing 1.69 MBq (45.5 mCi) of
activity was added to 5 ml of human serum (0.337 MBq ml–1,
9.1 mCi ml–1) and incubated at 37°C. Serum samples of 500 ml
were taken at 5 min, 4, 24, 48, 72 and 96 h, filtered and run on the
FPLC Superose-6 column as described above.
In addition, 111In-DTPA-labelled pegylated liposomes
containing 2.7 MBq (73 mCi) of activity were added to 8 ml of
human serum (0.337 MBq ml–1, 9.1 mCi ml–1) and incubated at
37°C. Serum samples of 500 ml were taken at 30 min, 4, 24, 48, 72,
96 and 240 h, filtered and run on the FPLC Superose-6 column as
described above.
RESULTS
Pharmacokinetics and biodistribution of 111In-DTPA-
labelled pegylated liposomes
Data were available for a total of 112 animals studied at the
various time-points, although not all tissues were sampled for each
animal at each time-point. The detailed biodistribution of 111In-
DTPA-labeled pegylated liposomes in nude mice bearing KB head
and neck cancer xenograft tumours is presented in Table 1. The
mean tumour weight was 0.46 ± 0.39 g (median 0.338, range
0.026–2.083).
The t1/2a and t1/2b circulation half-lives of 111In-DTPA-labeled
pegylated liposomes were determined using the P.Fit program
(Biosoft, Cambridge, UK) which fitted the blood data for the first
96 h to the biexponential decay equation:
y = P e–ax + Q e–bx
The t1/2a and t1/2b were 1.1 and 10.3 h, respectively. The good-
ness of fit was within 95% of expected limits for a correct model of
the data (r2 = 0.996). The data were also fitted to a monoexponen-
tial function which gave a half-life of 10.1 h (r2 = 0.972).
Localization of pegylated liposomes in xenograft tumours was
demonstrated at low levels at early time-points, but there was
evidence of progressive accumulation to a maximum of 5.5 ± 3.0%
ID g–1 at 24 h. Thereafter the levels measured in the tumour
declined slowly with time (Figure 1). The tumour: blood ratios
were 0.04:1 at 1 h, 0.09:1 at 4 h, 0.75:1 at 24 h, 2.9:1 at 48 h,
13.5:1 at 72 h, 47.5:1 at 96 h, 50.0:1 at 144 h and 40.0:1 at 240 h.
The levels of liposome uptake in the clinically relevant tissues
of the liver, spleen, heart and skin are shown in Figure 2.
Prominent uptake of pegylated liposomes in the liver, spleen and
kidneys was demonstrated, reaching maximal levels at 24 h of
19.3 ± 2.8, 18.8 ± 4.2 and 6.7 ± 1.9% ID g–1, respectively.
Cutaneous deposition of activity increased to a maximum of
4.5  ± 1.4% ID g–1 at 24 h and remained at this level until 72 h after
injection, whereupon it declined gradually. Significant accumula-
tion of radiolabeled liposomes was seen in the uterus and ovary to
maximal levels of 6.6 ± 2.9 and 3.5 ± 0.7% ID g–1 at 48 and 24 h,
respectively. There was evidence of uptake in tissues of the
gastrointestinal tract, although this did not seem to be due to
biliary excretion as demonstrated by the low levels of activity in
the gallbladder. Liposome uptake in lung, heart, and adrenal
glands declined progressively throughout the time course of the
study from maximal values at 1 h, with no evidence of progressive
accumulation. Very low levels of liposome localization were seen
in the tissues of the central nervous system and musculoskeletal
system. The high initial levels of 111In (56.1 ± 38.1% ID g–1)
measured in the urine at the 1 h time-point almost certainly repre-
sent excretion of unencapsulated EDTA-bound radioisotope. The
relatively low levels of urinary radioisotope excretion on subse-
quent days probably reflects the gradual release of 111In-DTPA
from degraded liposomes.
Pharmacokinetics and biodistribution of
unencapsulated 111In-DTPA
Data were available for a total of 28 mice, four at each dissection
time-point. The detailed biodistribution of 111In-DTPA in nude
mice bearing KB head and neck cancer xenograft tumours is
Table 1 Biodistribution of 111In-DTPA-labelled pegylated liposomes in nude mice expressed in % injected dose per gram (mean ± SD)
Tissue 1 h 4 h 24 h 48 h 72 h 96 h 144 h 240 h
Blood 33.2 (5.4) 20.6 (1.7) 7.3 (2.6) 1.4 (1.0) 0.2 (0.1) 0.04 (0.01) 0.02 (0.00) 0.01 (0.00)
Urine 56.1 (38.1) 7.7 (3.5) 6.0 (2.8) 9.2 (3.9) 10.0 (3.3) 10.0 (9.2) 4.5 (1.0) 1.1 (0.4)
Tumour 1.2 (0.3) 1.8 (0.2) 5.5 (3.0) 4.1 (2.0) 2.7 (0.9) 1.9 (1.0) 1.0 (0.4) 0.4 (0.1)
Liver 6.4 (1.2) 9.0 (1.2) 19.3 (2.8) 17.2 (3.9) 15.4 (3.7) 12.8 (3.2) 9.6 (2.4) 2.7 (1.0)
Spleen 8.4 (1.7) 8.5 (0.7) 18.8 (4.2) 16.3 (6.4) 13.4 (4.0) 12.5 (3.5) 10.2 (3.0) 4.7 (0.9)
Lung 7.9 (3.3) 5.0 (2.6) 2.2 (0.8) 1.2 (1.3) 0.6 (0.2) 0.4 (0.2) 0.25 (0.08) 0.17 (0.04)
Kidney 6.3 (1.6) 4.8 (0.9) 6.7 (1.9) 6.0 (2.7) 5.3 (2.5) 4.3 (1.5) 2.5 (0.6) 2.2 (0.4)
Bladder 1.2 (0.2) 1.0 (0.2) 1.3 (0.3) 0.6 (0.3) 0.57 (0.04) 0.8 (0.3) 0.38 (0.06) 0.28 (0.16)
Oesophagus 2.5 (0.5) 2.4 (1.1) 4.2 (3.1) 1.0 (0.4) 1.0 (0.4) 1.6 (1.5) 0.5 (0.1) 0.2 (0.2)
Stomach 0.8 (0.1) 0.6 (0.1) 1.1 (0.4) 0.9 (0.5) 0.7 (0.3) 0.4 (0.1) 0.3 (0.1) 0.15 (0.03)
Ileum 1.2 (0.2) 1.2 (0.2) 2.0 (0.6) 1.3 (0.4) 1.1 (0.3) 0.8 (0.1) 0.7 (0.3) 0.4 (0.2)
Colon 1.2 (0.6) 0.9 (0.1) 2.3 (0.6) 2.2 (0.4) 1.9 (0.2) 1.8 (0.7) 0.5 (0.1) 0.4 (0.1)
Pancreas 1.1 (0.1) 1.1 (0.2) 0.8 (0.4) 0.30 (0.06) 0.5 (0.1) 0.9 (0.9) 0.25 (0.09) 0.21 (0.03)
Gallbladder 1.4 (0.8) 0.5 (0.4) 0.4 (0.1) 0.5 (0.4) 0.09 (0.04) 0.2 (0.2) 0.07 (0.05) 0.10 (0.06)
Uterus 1.6 (0.6) 2.8 (0.9) 5.0 (1.3) 6.6 (2.9) 4.9 (5.0) 2.9 (2.3) 3.4 (1.7) 2.8 (1.7)
Ovary 1.6 (0.2) 1.6 (0.4) 3.5 (0.7) 2.0 (0.8) 1.6 (0.6) 1.6 (0.9) 1.3 (0.6) 0.9 (0.4)
Skin 1.1 (0.2) 1.6 (0.3) 4.5 (1.4) 4.2 (1.8) 4.5 (2.7) 3.3 (2.3) 1.6 (0.9) 1.1 (0.1)
Heart 3.3 (0.4) 1.8 (0.6) 1.3 (0.6) 0.8 (0.6) 0.8 (0.7) 0.4 (0.3) 0.20 (0.10) 0.21 (0.02)
Adrenal 4.3 (0.7) 3.4 (0.6) 2.6 (1.0) 1.2 (0.3) 1.2 (0.2) 0.9 (0.1) 1.0 (0.2) 0.4 (0.1)
Bone 1.7 (0.3) 0.8 (0.1) 1.1 (0.4) 0.7 (0.4) 0.7 (0.4) 0.6 (0.3) 0.5 (0.3) 0.3 (0.1)
Muscle 0.4 (0.1) 0.31 (0.03) 0.30 (0.10) 0.24 (0.13) 0.16 (0.06) 0.11 (0.04) 0.12 (0.08) 0.08 (0.07)
Brain 0.7 (0.1) 0.5 (0.1) 0.13 (0.06) 0.03 (0.02) 0.01 (0.00) 0.01 (0.00) 0.01 (0.00) 0.01 (0.00)
Spinal cord 2.1 (0.5) 1.7 (0.9) 0.4 (0.3) 0.09 (0.06) 0.05 (0.04) 0.02 (0.00) 0.03 (0.02) 0.01 (0.00)Biodistribution of pegylated liposomes in nude mice 235
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presented in Table 2. The mean tumour weight was 0.40 ± 0.26 g
(median 0.356, range 0.094–0.912).
The t1/2a and t1/2b were 5 min and 1.1 h, respectively. The good-
ness of fit was within 95% of expected limits for a correct model
of the data. This rapid blood clearance of 111In-DTPA was associ-
ated with very high levels of radioactivity excreted in the urine at
the early time-points. Maximum tumour 111In activity was seen at
5 min. There was no evidence of cumulative deposition of 111In-
DTPA in the tumour or, indeed, in any normal tissue. These data,
together with the very short half-life of 111In-DTPA in the circula-
tion, suggest that 111In-DTPA in unlikely to become bound to
serum proteins to any significant extent.
Incubation of 111InCl3, 111In-DTPA and in vitro stability of
111In-DTPA-labeled pegylated liposomes in human
serum
The results of running samples of 111InCl3 incubated in human
serum on the Superose-6 FPLC column are presented in Figure 3A.
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Figure 1 Blood and tumour levels of 111In-DTPA-labelled pegylated
liposomes and 111In-DTPA in nude mice bearing KB xenograft tumours.
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Figure 2 Biodistribution of (A) 111In-DTPA-labelled pegylated liposomes and
(B) unencapsulated 111In-DTPA in nude mice bearing KB xenograft tumours.
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Figure 3 (A) Incubation of 111In chloride in human serum for 120 h: FPLC
Superose-6 column. (B) Inclubation of 111In-DTPA in human serum for 96 h.
(C) Inclubation of 111In-DTPA-labelled pegylated liposomes in human serum
for 240 h.
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The activity of the 111InCl3 control was collected between fractions
39 and 80, with a peak at fraction 45. The sample taken at
5 min showed a significant shift in the distribution of activity to
between fractions 33–50, with a peak activity at fraction 42. These
results are consistent with rapid binding of the 111In to serum
proteins, most probably transferrin.
The results of running samples of 111In-DTPA incubated in
human serum on the Superose-6 FPLC column are presented in
Figure 3B. The activity of the 111In-DPTA control was collected
between fractions 42 and 52, with a peak at fraction 46. The
samples taken at the various time-points after addition to serum
demonstrated an earlier shoulder to the curve starting at fraction
38. These data suggest that 111In-DTPA is very stable in serum,
with only very low levels of transchelation of the 111In to serum
proteins.
The results of incubation of 111In-DTPA-labelled pegylated lipo-
somes in human serum over a period of 240 h are presented in
Figure 3C. The radioactivity of the radiolabelled pegylated lipo-
somes was collected between fractions 19 and 40 and the free
indium activity was collected between fractions 49 and 60 on the
FPLC Superose-6 column. As can be seen from Figure 3C, there is
very little accumulation of free 111In-DTPA in the serum and no
evidence of significant transchelation of 111In to a serum protein,
which would be expected to run with a peak at about fraction 42.
DISCUSSION
This study confirms the ability of 111In-DTPA-labelled pegylated
liposomes to target KB xenograft tumours in nude mice and yields
a detailed description of their biodistribution in a wide range of
normal tissues and organ systems. These data contrast directly
with those for the behaviour of unencapsulated 111In-DTPA, which
is cleared very rapidly from the circulation with no evidence of
accumulation in either tumour or normal tissues. The absence of
leakage of 111In-DTPA from the pegylated liposomes and the
virtual lack of transchelation of 111In to serum proteins when either
111In-DTPA-labelled pegylated liposomes or free 111In-DTPA were
incubated in human serum excludes the possibility that the demon-
strated uptake is due to targeting by radiolabelled serum elements,
such as transferrin.
The data on myocardial and cutaneous uptake agree with the
available clinical data for pegylated liposomes containing doxoru-
bicin. Low levels of uptake of 111In-DTPA-labelled pegylated lipo-
somes were demonstrated in the myocardium, with an area under
the time activity curve (AUC) of 132% ID g–1 h as compared to
489% ID g–1 h for blood for the 240 h period of the study.
Importantly, there was no cumulative liposome deposition in
cardiac muscle, which correlates well with the documented lack of
cardiotoxicity of pegylated liposomal doxorubicin. This contrasts
with the high levels of uptake seen in the skin and the profile of
cumulative deposition over the first 72 h after injection. The AUC
of 615% ID g–1 h for the radiolabelled liposomes supports the
notion that this would lead to prolonged drug exposure in the skin
and provides an explanation of the occurrence of PPE with
pegylated liposomal doxorubicin in patients. Therefore, the data
generated by this study may provide a useful predictor of the likely
adverse effects of pegylated liposomal drug formulations and
guide the design and development of novel targeted strategies.
The development of novel liposomal formulations of well estab-
lished cytotoxic drugs holds the promise of increasing treatment
response rates and favorably altering the toxicity profile of the
entrapped agents. A number of cytotoxic agents (including anthra-
cyclines, platins and vinca alkaloids) have been successfully pack-
aged within pegylated liposomes and are in various stages of
pre-clinical and clinical development (Martin, 1997). In addition,
the opportunity to design a range of new liposomally-targeted
therapeutic agents may prove to be equally fruitful. For
example, preclinical assessment of pegylated liposome-entrapped
radiosensitizers and therapeutic beta-emitting radionuclides is
proceeding in our laboratory. In the former instance, a number of
Table 2 Biodistribution of 111In-DTPA in nude mice expressed in % injected dose per gram (mean ± SD)
Tissue 5 min 30 min 1 h 4 h 24 h 48 h 72 h
Blood 7.2 (1.5) 0.45 (0.08) 0.20 (0.03) 0.07 (0.00) 0.01 (0.01) 0.006 (0.000) 0.004 (0.001)
Urine 783 (956) 2145 (228) 756 (117) 5.1 (3.2) 0.3 (0.2) 0.10 (0.01) 0.07 (0.01)
Tumour 1.0 (0.2) 0.30 (0.03) 0.30 (0.03) 0.11 (0.01) 0.05 (0.00) 0.05 (0.02) 0.03 (0.01)
Liver 1.4 (0.2) 0.18 (0.04) 0.15 (0.02) 0.13 (0.02) 0.09 (0.01) 0.07 (0.01) 0.06 (0.01)
Spleen 0.9 (0.3) 0.09 (0.01) 0.08 (0.01) 0.07 (0.01) 0.08 (0.01) 0.06 (0.01) 0.05 (0.01)
Lung 3.8 (0.8) 0.32 (0.06) 0.14 (0.04) 0.06 (0.01) 0.04 (0.01) 0.03 (0.01) 0.03 (0.01)
Kidney 16.4 (4.8) 1.6 (0.1) 1.2 (0.1) 1.1 (0.2) 0.8 (0.1) 0.5 (0.1) 0.4 (0.2)
Bladder 11.9 (4.9) 7.0 (3.0) 4.8 (8.1) 1.5 (0.6) 0.23 (0.08) 0.18 (0.06) 0.28 (0.13)
Oesophagus 4.3 (0.7) 0.9 (0.4) 0.24 (0.15) 0.20 (0.12) 0.05 (0.01) 0.16 (0.25) 0.13 (0.02)
Stomach 1.3 (0.4) 0.11 (0.04) 0.07 (0.02) 0.16 (0.18) 0.04 (0.01) 0.02 (0.01) 0.02 (0.00)
Ileum 0.9 (0.3) 0.11 (0.04) 0.08 (0.03) 0.12 (0.13) 0.06 (0.01) 0.05 (0.02) 0.03 (0.01)
Colon 1.4 (0.3) 0.11 (0.03) 0.07 (0.01) 0.8 (1.4) 0.05 (0.01) 0.03 (0.01) 0.02 (0.01)
Gallbladder 2.0 (0.9) 0.3 (0.2) 0.7 (0.3) 0.2 (0.1) 0.03 (0.02) 0.02 (0.02) 0.01 (0.01)
Pancreas 1.4 (0.2) 0.23 (0.02) 0.06 (0.04) 0.04 (0.02) 0.03 (0.01) 0.03 (0.01) 0.03 (0.01)
Uterus 8.0 (3.6) 1.6 (2.3) 0.2 (0.1) 0.08 (0.03) 0.06 (0.03) 0.07 (0.02) 0.09 (0.02)
Ovary 4.0 (0.7) 0.9 (0.3) 0.1 (0.1) 0.08 (0.03) 0.08 (0.03) 0.05 (0.02) 0.05 (0.02)
Skin 3.9 (0.8) 0.3 (0.1) 0.2 (0.1) 0.12 (0.01) 0.10 (0.02) 0.07 (0.01) 0.08 (0.02)
Heart 1.5 (0.3) 0.12 (0.03) 0.08 (0.01) 0.04 (0.01) 0.03 (0.00) 0.02 (0.01) 0.02 (0.00)
Adrenal 2.9 (0.4) 0.27 (0.04) 1.4 (2.0) 0.17 (0.03) 0.09 (0.04) 0.05 (0.03) 0.04 (0.03)
Bone 0.7 (0.1) 0.06 (0.01) 0.06 (0.03) 0.04 (0.00) 0.04 (0.02) 0.03 (0.01) 0.02 (0.01)
Muscle 0.8 (0.1) 0.06 (0.02) 0.16 (0.24) 0.03 (0.01) 0.02 (0.01) 0.02 (0.01) 0.01 (0.01)
Brain 0.2 (0.1) 0.03 (0.00) 0.16 (0.25) 0.01 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Spinal cord 1.2 (0.7) 0.08 (0.02) 0.27 (0.06) 0.07 (0.03) 0.01 (0.00) 0.00 (0.00) 0.00 (0.00)Biodistribution of pegylated liposomes in nude mice 237
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different classes of drugs have been described which have the
property of sensitizing tumours to the effects of ionizing radiation
(McGinn and Kinsella, 1992; Saunders and Dische, 1996; Britten
et al, 1996). Unfortunately, radiosensitization of normal tissues
included in the radiation portal and the occurrence of dose-limiting
systemic toxicities have severely limited the clinical application of
these agents. Liposomal entrapment of radiosensitizers may
circumvent these problems by delivering the active agent preferen-
tially to the tumour site, while avoiding deposition in adjacent and
distant normal tissues which are sensitive to toxic effects of the
unencapsulated agent. From this study, the use of liposomally-
targeted radiosensitizers would seem to be a suitable approach for
further investigation in patients with cancers of the lung, oesoph-
agus and head and neck. For patients with lung and oesophageal
cancers, the dose-limiting late-responding normal structures are
the adjacent normal ipsilateral lung tissue, the contralateral lung
and the thoracic spinal cord. Radiosensitization in these tissues
would be expected to have an adverse effect on outcome and limit
the effective radiation dose that could be delivered safely. The low
levels of liposome uptake within the lung and thoracic/cervical
spinal cord suggest that this would not be a significant risk.
Similarly, in patients receiving radical radiotherapy to head and
neck cancers, the dose delivered to the cervical spinal cord deter-
mines the risk of cervical myelopathy. This study suggests that no
significant radiosensitization of this structure would occur with the
use of liposomally-entrapped radiosensitizing drugs. Detailed data
regarding the localization of liposomes to the normal mucosal
structures of the head and neck are not available from this murine
model, but an ongoing patient study is presently addressing that
issue. The moderate levels of uptake in tissues of the gastroin-
testinal tract would suggest that liposomally-targeted radiosensi-
tizing drugs would need to be used with caution in patients with
pelvic tumours, e.g. cervix, bladder and rectal cancers, although
the established radioresponsiveness of these tumour types would
certainly justify further examination of this novel approach. On the
other hand, the relatively high levels of uptake seen in the liver,
spleen and kidneys are likely to preclude the use of liposomal
radiosensitizers in treating patients with tumours of the upper
abdomen, e.g. pancreatic cancers, because normal tissues might be
expected to experience an unacceptable degree of radio-
sensitization.
The use of liposomally-encapsulated beta-emitting radionu-
clides as a means of delivering a local radiation boost to the
primary tumour and metastatic lymph nodes during a course of
external beam radiotherapy may be of clinical use in an analogous
fashion to that previously described for radiolabelled monoclonal
antibodies (Maraveyas et al, 1995). Clearly this system would be
most likely to be of benefit in patients with tumours in regions
where liposomal targeting of adjacent critical normal structures
would be minimal. For instance, patients with head and neck or
lung cancers would be suitable candidates for such an approach,
since the normal tissues (liver, spleen and kidneys) receiving a
significant radiation dose from radiolabelled liposomes would not
receive any of the dose delivered by the external beam radio-
therapy. On the other hand, in patients with tumours of the
pancreas, the additional liposomally-targeted radiation delivered
to the liver, spleen and kidneys would be likely to result in severe
toxicity since these tissues would have already received an
external beam radiotherapy dose at or near radiotolerance.
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